To the Editor: Metastatic melanoma is a fatal disease with rapid systemic dissemination and a 5-year survival rate of about 17%. [1] More than half of primary metastases involve the skin as nodal, subcutaneous, or distant metastasis. [2] Cutaneous metastases of melanoma occur relatively frequently and can arise in early-or late-stage disease, with a variable clinical appearance and pattern distribution. [3] We describe herein a patient with a large subcutaneous nodule on the arm that we initially diagnosed as a lipoma. After obtaining further clinical history and reviewing the pathologic findings after excision, the nodule was determined to represent metastatic melanoma.
A 71-year-old woman presented with an egg-sized, soft, non-tender, subcutaneous nodule on the lateral left upper arm. Ultrasonic examination revealed a hypoechoic nodule in the subcutaneous adipose layer, measuring 4.5 cm Â 2.5 cm [ Figure 1A ]. Histopathologic examination of a biopsy specimen was consistent with lipoma. After sterilizing the site and administering local anesthesia, an incision was made about 0.1 cm from the edge of the mass. The mass was dissected completely and determined to be entirely contained in the subcutaneous layer. Gross examination of the tumor showed an ellipsoid, uneven surface with an incomplete envelope surrounding the mass, which measured 5 cm Â 3 cm. Sectioning the mass revealed a mixture of colors -grayish-white, grayish-yellow, and grayish-brown -and a rough texture [ Figure 1B and 1C].
Three years ago, the patient underwent amputation of her left thumb for malignant melanoma. Given this history, we were highly suspicious that this mass was not actually a lipoma but rather metastatic melanoma. Histopathologic testing confirmed this diagnosis. The tumor cells were spindle shaped, with large oval nuclei, clear nucleoli, many mitotic figures, and a large number of melanin deposits in the cytoplasm. The cells formed a diffuse distribution pattern [ Figure 1D ]. Immunohistochemical staining revealed the mass to be positive for melan A, human melanoma black 45 (HMB-45), S-100 protein, and sryrelated HMg-box gene 10 (SOX-10) [ Figure 1E1 -1E4].
Examination using positron emission tomography-computed tomography revealed multiple metastatic disseminated lesions in the left axillary lymph nodes, the proximal muscles of the left upper extremity, and the lungs. Ultrasound-guided puncture biopsy of an enlarged lymph node confirmed metastatic melanoma with tumor cells arranged in patches, with large, dark nuclei, and visible atypia. The cytoplasm contained melanin, and the structure of the lymph node was destroyed [ Figure 1F ]. Immunohistochemical staining of the lymph node was positive for Melan A, HMB-45, S-100, and SOX-10 [ Figure 1G1 -1G4]. The patient was given subcutaneous a-2b interferon, 3 million units every other day, and followed up every 3 months. She had no adverse reaction to interferon treatment.
Skin metastases of melanoma can present as local recurrences, as in-transit disease, or as distant metastases, depending on the distance from the primary lesion. We report herein a patient with an in-transit metastasis of melanoma that was misdiagnosed as a lipoma before surgery. The reason for this misdiagnosis may be that no actual neoplastic tissue, only a sample of the superficial adipose layer, was obtained on the preoperative biopsy. It is also possible that some normal adipose tissue existed within the mass.
This case highlights the importance of clinical history, of having a high level of suspicion when evaluating any pigmented lesion, and of close follow-up after a diagnosis of melanoma. A very high rate of metastasis occurs in patients with melanoma, even in those who initially present with early stage disease.
[4] All patients with early stage melanoma must undergo a strict, thorough, and close follow-up program for at least 2 years after diagnosis. Administration of the bacillus Calmette-Guerin vaccine and interferon treatment are recommended for patients with in-transit metastasis.
[5] Our patient had refused systemic treatment and routine follow-up for 3 years after her initial surgery. Close follow-up and biotherapy are essential for prolonging survival in patients with melanoma.
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